Ann: CelGro Study Results Open Up New US Market Access Strategy, page-17

Orthocell have made some very big claims today as to the efficaciousness of their CelGro product. If the FDA agree with their conclusions, they may allow an expedited approval pathway. This would bring forward cash generation and represent a massive marketing coup against leading competitors. Whilst we must wait for the completed human clinical trial results in the current quarter...the potential market is very high value.. By concentrating on rehabilitation of patients with tetraplegia, they may have the potential to establish reimbursement levels which are multiples of industry norms because they claim unique therapeutic characteristics. The market might initially ignore these type of announcements... but they certainly should not ignore any positive deliberations by the FDA with regard to an accelerated approval pathway. Getting closer !